Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sobi Realigns Focus On Late-Stage Hematology & Immunology Assets

Executive Summary

Swedish specialty pharma and rare diseases company seeks to sustain recent rapid revenues growth with increased R&D focus and investments in its hematology and immunology franchises.

You may also be interested in...



Deal Watch: Sanofi Further Opts Out Of CNS Tie-Up With Voyager

Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.

Novimmune Sells Gamifant And IO Assets To Sobi

Swiss biotech Novimmune SA creates newco around Gamifant emapalumab and other immuno-oncology assets and then sells it to Sobi for CHF515m ($519.2m).

Sobi Advances Growth Strategy With Gamifant Launch In Early 2019 For Primary HLH

The interferon gamma blocker is the first new therapy for HLH in 24 years. FDA approval came about four months after Sobi acquired global rights from NovImmune in a deal meant to improve the company's growth prospects.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125391

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel